Interleukin Genetics, Inc. develops and markets genetic tests for chronic diseases and health-related conditions. The Company operates through the genetic test business segment. The Company's products include PerioPredict genetic test and Inherent Health line of genetic tests. PerioPredict is a genetic risk test that analyzes genetic variations associated with inflammation and identifies individuals with a life-long predisposition to over-produce inflammation. PerioPredict identifies specific polymorphisms (genetic variations) in genes that regulate the production of interleukin-1 cytokines. PerioPredict identifies adults at increased risk for severe periodontal disease. The Company markets additional genetic tests through its Inherent Heath brand. Its additional genetic tests include weight management genetic test, bone health genetic test, heart health genetic test, nutritional needs genetic test and wellness select genetic test.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:ILIU
- CUSIP: N/A
- Web: www.ilgenetics.com
- Market Cap: $2.8 million
- Outstanding Shares: 229,471,000
- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.09
- 52 Week Range: $0.01 - $0.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.60
- P/E Growth: 0.000
- Annual Revenue: $1.75 million
- Price / Sales: 1.57
- Book Value: ($0.02) per share
- Price / Book: -0.55
- EBIDTA: ($7,370,000.00)
- Net Margins: -481.82%
- Return on Assets: -237.71%
- Debt-to-Equity Ratio: -0.16%
- Current Ratio: 0.23%
- Quick Ratio: 0.22%
- Average Volume: 96,764 shs.
- Beta: 1.35
- Short Ratio: 4
Frequently Asked Questions for Interleukin Genetics (OTCMKTS:ILIU)
What is Interleukin Genetics' stock symbol?
Interleukin Genetics trades on the OTCMKTS under the ticker symbol "ILIU."
How were Interleukin Genetics' earnings last quarter?
Interleukin Genetics Inc. (OTCMKTS:ILIU) issued its quarterly earnings results on Friday, May, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.20 million during the quarter. View Interleukin Genetics' Earnings History.
Who are some of Interleukin Genetics' key competitors?
Some companies that are related to Interleukin Genetics include Strata Skin Sciences (SSKN), NeuroMetrix (NURO), Windtree Therapeutics (WINT), Critical Outcome T (COTQF), Affymax (AFFY), Adeptus Health (ADPT), DNIB Unwind (BIND), Echo Therapeutics (ECTE), Epirus Biopharmaceuticals (EPRS), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX), Parnell Pharmaceuticals Holdings Ltd (PARN), Secure Point Technologies (IMSC), Sunshine Heart (SSH), Tetralogic Pharmaceuticals Corp (TLOG) and Unilife Corp (UNIS).
Who are Interleukin Genetics' key executives?
Interleukin Genetics' management team includes the folowing people:
- James M. Weaver, Independent Chairman of the Board
- Kenneth S. Kornman Ph.D. DDS, President, Chief Scientific Officer, Director
- Mark B. Carbeau, Chief Executive Officer, Director
- Stephen J. DiPalma, Interim Chief Financial Officer
- Stephan Toutain, Chief Commercial Officer
- Lionel Carnot, Independent Director
- Joseph M. Landstra, Independent Director
- William C. Mills III, Independent Director
- Dayton C. Misfeldt, Independent Director
How do I buy Interleukin Genetics stock?
Shares of Interleukin Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Interleukin Genetics' stock price today?
MarketBeat Community Rating for Interleukin Genetics (OTCMKTS ILIU)MarketBeat's community ratings are surveys of what our community members think about Interleukin Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Interleukin Genetics stock can currently be purchased for approximately $0.01.
Consensus Ratings for Interleukin Genetics (OTCMKTS:ILIU) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Interleukin Genetics (OTCMKTS:ILIU)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Interleukin Genetics (OTCMKTS:ILIU)Earnings History by Quarter for Interleukin Genetics (OTCMKTS ILIU)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/12/2017||Q1 2017||($0.01)||$0.20 million||View||N/A|
|11/15/2016||Q3 2016||($0.01)||$0.73 million||View||N/A|
|8/15/2016||Q2||($0.01)||($0.01)||$0.25 million||$0.59 million||View||Listen|
|5/12/2016||Q1||($0.01)||($0.01)||$0.27 million||$0.96 million||View||Listen|
|3/17/2016||Q4||($0.01)||($0.01)||$0.31 million||$0.37 million||View||Listen|
|11/12/2015||Q3||($0.01)||($0.01)||$0.36 million||$0.30 million||View||N/A|
|8/14/2015||Q2||($0.01)||($0.01)||$0.37 million||$0.38 million||View||Listen|
|3/20/2015||Q4 2014||($0.01)||($0.01)||$0.52 million||$0.32 million||View||N/A|
|11/14/2014||Q3 2014||($0.01)||($0.01)||$0.58 million||$0.47 million||View||N/A|
|8/13/2014||Q2 2014||($0.01)||($0.01)||$0.47 million||$0.53 million||View||N/A|
|3/20/2014||Q4 13||($0.01)||($0.02)||$0.54 million||$0.67 million||View||N/A|
Earnings Estimates for Interleukin Genetics (OTCMKTS:ILIU)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-0.02 EPS
Dividend History for Interleukin Genetics (OTCMKTS:ILIU)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Interleukin Genetics (OTCMKTS:ILIU)
Insider Ownership Percentage: 54.40%Insider Trades by Quarter for Interleukin Genetics (OTCMKTS:ILIU)
Institutional Ownership Percentage: 0.27%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/29/2016||Bay City Capital Fund V, L.P.||Major Shareholder||Buy||30,181,086||$0.10||$3,018,108.60|| |
|7/29/2016||Kenneth S. Kornman||Insider||Buy||25,150||$0.10||$2,515.00|| |
|7/29/2016||Stephen J Dipalma||CFO||Buy||100,603||$0.10||$10,060.30|| |
|12/23/2014||Bay City Capital Llc||Major Shareholder||Buy||26,491,952||$0.10||$2,649,195.20|| |
|12/23/2014||Stephen J Dipalma||CFO||Buy||249,252||$0.10||$24,925.20|| |
Headline Trends for Interleukin Genetics (OTCMKTS:ILIU)
Latest Headlines for Interleukin Genetics (OTCMKTS:ILIU)
Interleukin Genetics (ILIU) Chart for Tuesday, July, 25, 2017